• TempraMed entered a strategic partnership with Stealth Health to integrate its VIVI medication-protection products into Stealth Health’s telemedicine platform.
• Stealth Health will recommend and distribute the VIVI portfolio through its direct-to-patient clinic, expanded via its white-label network.
• Deal targets patients using temperature-sensitive therapies such as hormones, peptides, GLP-1s, positioning VIVI as an adjunct standard of care.
• Channel adds North American reach through Stealth Health’s HIPAA-certified, MSO-compliant infrastructure operating across all 50 U.S. states.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempramed Technologies Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608040700NEWSFILECNPR____20260804_307851_1) on August 04, 2026, and is solely responsible for the information contained therein.